Side effects such as hair loss have been reported by several of the major manufacturers: Eli Lilly, which sells Mounjaro, and Novo Nordisk, which sells Wegovy and Ozempic.
And with about one in eight American adults using GLP-1 weight-loss drugs, there are significant growth opportunities for the hair industry, CNBC reports.
Several companies that sell products intended to stimulate hair growth have also noticed increased demand, CNBC reports, citing surveys and company statements.
Corrected: In an earlier version of the text there were several errors, including the wording about the preferred form of the weight-loss drugs and which companies sell which drugs. It also corrected the spelling of Wegovy.
